Track whether actual FDA guidance or DEA scheduling changes materialize within 90 days—policy announcements without regulatory follow-through are classic distraction plays.
This policy reversal carries no constitutional damage—it's a standard executive policy shift on drug regulation within existing FDA/DEA frameworks. However, it scores moderately high on distraction: high novelty (psychedelics are culturally resonant), excellent media friendliness (easy panel discussions, bipartisan appeal), and strategic timing alongside multiple election-integrity and DOJ enforcement actions. The 'reversal' framing amplifies coverage beyond governance substance.